52333-87-6

Basic information

• Product Name: 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine
• Synonyms: 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine;2-(p-Tolyl)oxazolo[4,5-b]pyridine;2-(4-methylphenyl)-Oxazolo[4,5-b]pyridine
• CAS NO: 52333-87-6
• Molecular Formula: C₁₃H₁₀N₂O
• Molecular Weight: 210
• Mol File: 52333-87-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine(52333-87-6)
• EPA Substance Registry System: 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine(52333-87-6)

Safety Data

• Hazardous Substances Data: 52333-87-6(Hazardous Substances Data)

Usage

General Description

2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine is a chemical compound with a complex molecular structure. It belongs to the oxazolo[4,5-b]pyridine family, which is known for its diverse pharmacological properties. 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine is often used in pharmaceutical research and drug development due to its potential therapeutic effects. It is believed to have biological activity related to the central nervous system and is being studied for its potential as a treatment for various neurological disorders. Additionally, it may also have applications in the field of organic synthesis and material science. However, further research is needed to fully understand the potential uses and effects of this compound.

Upstream product

• 16867-03-1 2-amino-3-hydroxypyridine 
• 7559-36-6 4-methyl-β-nitrostyrene 
• 99-94-5 p-Toluic acid 
• 52334-57-3 N¹-(3-hydroxy-2-pyridyl)-4-methylbenzamide 
• 624-31-7 4-tolyl iodide 
• 273-97-2 oxazolo<4,5-b>pyridine 

Relevant articles and documents

Molecular modeling, density functional theory, ADME prediction and antimicrobial activity studies of 2-(substituted)oxazolo[4,5-: B] pyridine derivatives

In this study, the antimicrobial activities of previously synthesized 2-(substituted)oxazolo[4,5-b]pyridine derivatives toward six bacteria strains and twelve related drug-resistant isolates, and one fungus strain and two related drug-resistant isolates w

In vitro and in silico evaluation of 2-(substituted phenyl) oxazolo[4,5-b]pyridine derivatives as potential antibacterial agents

Increasing resistance to antibiotics is a major problem worldwide and stimulates the development of new bacterial inhibitors. Series of oxazolo[4,5-b]pyridine synthesized in our lab was examined to screen them as potential antimicrobial agents. The antimi

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.